News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
CLARIS Lifesciences Gets Nod for Rs 300-Crore IPO
November 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Economic Times -- Ahmedabad-based critical care and hospital products maker, Claris Lifesciences Ltd , has finally received approval from Securities and Exchange Board of India (SEBI) for its maiden public issue to raise Rs 300 crore.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Asia
MORE ON THIS TOPIC
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
·
2 min read
·
Tristan Manalac
IPO
2026 IPO blitz continues with 4 new biotech filings
September 22, 2026
·
4 min read
·
Tristan Manalac
Cancer
Boehringer Ingelheim bets up to $1B in AI-centered solid tumor collab with Envisagenics
September 22, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Western licensing deals for Chinese radioligand therapies to jump in 2027, Sleuth forecasts
September 21, 2026
·
2 min read
·
Nick Paul Taylor
